Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (241-250 of 331) with videos related to

Pageof 34
Sort By:
The New England Journal of Medicine|October 14, 2011
Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor, Jerry S Wolinsky, Christian Confavreux, et al.
Annals of Clinical and Translational Neurology|February 17, 2025
Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosisAhmed Bayoumi, Joseph A Thomas, Breanna R Alonzo, et al.
Archives of Neurology|February 15, 2001
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosisJ N Whitaker, J S Wolinsky, P A Narayana, et al.
The New England Journal of Medicine|May 8, 1975
Progressive rubella panencephalitis. Late onset after congenital rubellaJ J Townsend, J R Baringer, J S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2017
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studiesMark S Freedman, Jerry S Wolinsky, Giancarlo Comi, et al.
Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Neuroimage. Clinical|November 2, 2013
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center studyPonnada A Narayana, Koushik A Govindarajan, Priya Goel, et al.
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosisM S Freedman, J S Wolinsky, P Truffinet, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
Pageof 34

Showing results (241-250 of 331) with videos related to

Sort By:
Pageof 34
The New England Journal of Medicine|October 14, 2011
Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor, Jerry S Wolinsky, Christian Confavreux, et al.
Annals of Clinical and Translational Neurology|February 17, 2025
Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosisAhmed Bayoumi, Joseph A Thomas, Breanna R Alonzo, et al.
Archives of Neurology|February 15, 2001
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosisJ N Whitaker, J S Wolinsky, P A Narayana, et al.
The New England Journal of Medicine|May 8, 1975
Progressive rubella panencephalitis. Late onset after congenital rubellaJ J Townsend, J R Baringer, J S Wolinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2017
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studiesMark S Freedman, Jerry S Wolinsky, Giancarlo Comi, et al.
Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Neuroimage. Clinical|November 2, 2013
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center studyPonnada A Narayana, Koushik A Govindarajan, Priya Goel, et al.
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosisM S Freedman, J S Wolinsky, P Truffinet, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
Pageof 34